Fungemia after oral treatment with Saccharomyces boulardii in a patient with multiple co-morbidities;Fungämie nach oraler Gabe von Saccharomyces boulardii bei einem multimorbiden Patienten

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 48, 2003, Pages 2531-2533

  Lestin, F ^a   Pertschy, A ^a   Rimek, D ^a,b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Dezernat Medizinische Mikrobiologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; HEMOGLOBIN A1C; INSULIN; METRONIDAZOLE; PERENTEROL;

ADULT; ANEMIA; ARTERY DISEASE; ARTICLE; BLOOD CULTURE; CASE REPORT; COMORBIDITY; DIARRHEA; DISEASE ASSOCIATION; FEMOROPOPLITEAL BYPASS; FINGER; FOOT DISEASE; FUNGEMIA; GASTROENTERITIS; HUMAN; IMMUNE DEFICIENCY; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INTENSIVE CARE; LEG AMPUTATION; LEUKOCYTOSIS; MALE; MICROANGIOPATHY; MORTALITY; MULTIPLE ORGAN FAILURE; NECROSIS; RISK BENEFIT ANALYSIS; SACCHAROMYCES CEREVISIAE; SEPSIS; THROMBOCYTOSIS; TOXIC MEGACOLON;

ADMINISTRATION, ORAL; AMPUTATION; CLOSTRIDIUM DIFFICILE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; FATAL OUTCOME; FUNGEMIA; HUMANS; LEG; MALE; METRONIDAZOLE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROBIOTICS; SACCHAROMYCES CEREVISIAE; SAFETY;

EID: 0344303562     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-44948     Document Type: Article

References (13)

1. Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med 1998; 105: 71-72
2. Breves G, Faul K, Schröder B et al. Application of the colon-stimulation-technique for studying the effect of Saccharomyces boulardii on basic parameters of porcine cecal microbial metabolism disturbed by clindamycin. Digestion 2000; 61: 193-200
3. Castagliuolo I, LaMont JT, Nikulasson ST et al. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A - effects in the rat ileum. Infect Immun 1996; 64: 5225-5232
4. DeHoog GS, Guarro J, Gené J, Figueras MJ. Atlas of Clinical Fungi. 2nd ed (Hrsg). Centralbureau voor Schimmelcultures, Utrecht, Niederlande, 2000: 234-235
5. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhea: meta-analysis. BMJ 2002; 324: 1361-1364
6. Hennequin C, Kauffmann-Lacroix A, Jobert JP et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000; 19: 16-20
7. Hennequin C, Thierry A, Richard GF et al. Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. J Clin Microbiol 2001; 39: 551-559
8. McFarland LV, Surawicz CM, Greenberg RN et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995; 90: 439-448
9. Piarroux R, Millon L, Bardonnet K et al. Are live saccharomyces yeasts harmful to patients? Lancet 1999; 353: 1851-1852
10. Qamar A, Aboudola S, Warny M et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001; 69: 2762-2765
11. Surawicz CM, Elmer GW, Speelman P et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterol 1989; 96: 981-988
12. Surawicz CM, McFarland LV, Elmer GW et al. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastrenterol 1989; 84: 1285-1287
13. Surawicz CM, McFarland LV, Greenberg RN et al. The search for a better treatment of recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31: 1012-1017